{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:37:51Z","timestamp":1793144271962,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T00:00:00Z","timestamp":1583712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Faculdade de Medicina da USP - SP","award":["."],"award-info":[{"award-number":["."]}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"crossref","award":["2014\/09079-1"],"award-info":[{"award-number":["2014\/09079-1"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"crossref","award":["303379\/2018-9"],"award-info":[{"award-number":["303379\/2018-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s10067-020-05013-7","type":"journal-article","created":{"date-parts":[[2020,3,9]],"date-time":"2020-03-09T09:02:39Z","timestamp":1583744559000},"page":"2763-2771","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A prospective cross-sectional study of serum IL-17A in antisynthetase syndrome"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3470-4455","authenticated-orcid":false,"given":"Gustavo Luiz","family":"Behrens Pinto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8291-9616","authenticated-orcid":false,"given":"Renata Casseb de Souza","family":"Carboni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Henrique Carlos","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3682-4517","authenticated-orcid":false,"given":"Samuel Katsuyuki","family":"Shinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,9]]},"reference":[{"key":"5013_CR1","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","volume":"30","author":"L Gallay","year":"2018","unstructured":"Gallay L, Gayed C, Hervier B (2018) Antisynthetase syndrome pathogenesis: knowledge and uncertainties. Curr Opin Rheumatol 30:664\u2013673","journal-title":"Curr Opin Rheumatol"},{"key":"5013_CR2","first-page":"241","volume":"36","author":"PAO Araujo","year":"2018","unstructured":"Araujo PAO, Silva MG, Borba EF, Shinjo SK (2018) High prevalence of metabolic syndrome in antisynthetase syndrome. Clin Exp Rheumatol 36:241\u2013247","journal-title":"Clin Exp Rheumatol"},{"key":"5013_CR3","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1378\/chest.10-0180","volume":"138","author":"GR Connors","year":"2010","unstructured":"Connors GR, Christopher-Stine L, Oddis CV, Danoff SK (2010) Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years? Chest 138:1464\u20131474","journal-title":"Chest"},{"key":"5013_CR4","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","volume":"13","author":"JC Lega","year":"2014","unstructured":"Lega JC, Fabien N, Reynaud Q, Durieu I, Durupt S, Dutertre M, Cordier JF, Cottin V (2014) The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome. Autoimmun Rev 13:883\u2013891","journal-title":"Autoimmun Rev"},{"key":"5013_CR5","first-page":"73","volume":"53","author":"A Ro\u015fu","year":"2012","unstructured":"Ro\u015fu A, M\u01cerg\u01ceritescu C, Stepan A, Mu\u015fetescu A, Ene M (2012) IL-17 patterns in synovium, serum and synovial fluid from treatment-na\u00efve, early rheumatoid arthritis patients. Romanian J Morphol Embryol 53:73\u201380","journal-title":"Romanian J Morphol Embryol"},{"key":"5013_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.immuni.2011.02.012","volume":"34","author":"Y Iwakura","year":"2011","unstructured":"Iwakura Y, Ishigame H, Saijo S, Nakae S (2011) Functional specialization of interleukin-17 family members. Immunity 34:149\u2013162","journal-title":"Immunity"},{"key":"5013_CR7","doi-asserted-by":"publisher","first-page":"A028522","DOI":"10.1101\/cshperspect.a028522","volume":"10","author":"L Monin","year":"2018","unstructured":"Monin L, Gaffen SL (2018) Interleukin 17 family cytokines: signaling and therapeutic implications. Cold Spring Harb Perspect Biol 10:A028522","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"5013_CR8","doi-asserted-by":"publisher","first-page":"14292","DOI":"10.1073\/pnas.1009234107","volume":"107","author":"M Mitsdoerffer","year":"2010","unstructured":"Mitsdoerffer M, Lee Y, J\u00e4ger A, Kim HJ, Korn T, Kolls JK et al (2010) Pro-inflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci U S A 107:14292\u201314297","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5013_CR9","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12891-015-0710-3","volume":"16","author":"AM Reed","year":"2015","unstructured":"Reed AM, Crowson CS, Hein M, De Padilla CL, Olazagasti JM, Aggarwal R et al (2015) Biologic predictors of clinical improvement in rituximab-treated refractory myositis clinical rheumatology and osteoporosis. BMC Musculoskelet Disord 16:257","journal-title":"BMC Musculoskelet Disord"},{"key":"5013_CR10","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/art.30314","volume":"63","author":"FL Van De Veerdonk","year":"2011","unstructured":"Van De Veerdonk FL, Lauwerys B, Marijnissen RJ, Timmermans K, DI Padova F, Koenders MI et al (2011) The anti-CD20 antibody rituximab reduces the Th17 cell response. Arthritis Rheum 63:1507\u20131516","journal-title":"Arthritis Rheum"},{"key":"5013_CR11","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1111\/cei.12771","volume":"184","author":"A Alunno","year":"2016","unstructured":"Alunno A, Carubbi F, Bistoni O, Caterbi S, Bartoloni E, Di Benedetto P et al (2016) Interleukin (IL)-17-producing pathogenic T lymphocytes co-express CD20 and are depleted by rituximab in primary Sj\u00f6gren\u2019s syndrome: a pilot study. Clin Exp Immunol 184:284\u2013292","journal-title":"Clin Exp Immunol"},{"key":"5013_CR12","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s00005-015-0344-z","volume":"63","author":"J Tabarkiewicz","year":"2015","unstructured":"Tabarkiewicz J, Pogoda K, Karczmarczyk A, Pozarowski P, Giannopoulos K (2015) The role of IL-17 and Th17 lymphocytes in autoimmune diseases. Arch Immunol Ther Exp 63:435\u2013449","journal-title":"Arch Immunol Ther Exp"},{"key":"5013_CR13","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10875-009-9365-x","volume":"30","author":"XQ Chen","year":"2010","unstructured":"Chen XQ, Yu YC, Deng HH, Sun JZ, Dai Z, Wu YW et al (2010) Plasma IL-17A is increased in new-onset SLE patients and associated with disease activity. J Clin Immunol 30:221\u2013225","journal-title":"J Clin Immunol"},{"key":"5013_CR14","doi-asserted-by":"publisher","first-page":"e12649","DOI":"10.1111\/sji.12649","volume":"87","author":"LW Zhang","year":"2018","unstructured":"Zhang LW, Zhou PR, Wei P, Cong X, Wu LL, Hua H (2018) Expression of interleukin-17 in primary Sj\u00f6gren\u2019s syndrome and the correlation with disease severity: a systematic review and meta-analysis. Scand J Immunol 87:e12649","journal-title":"Scand J Immunol"},{"key":"5013_CR15","first-page":"656","volume":"37","author":"MG Silva","year":"2018","unstructured":"Silva MG, Oba-Shinjo SM, Marie SKN, Shinjo SK (2018) Serum interleukin-17A level is associated with disease activity of adult patients with dermatomyositis and polymyositis. Clin Exp Rheumatol 37:656\u2013662","journal-title":"Clin Exp Rheumatol"},{"key":"5013_CR16","doi-asserted-by":"publisher","first-page":"224","DOI":"10.3109\/03009742.2014.956141","volume":"44","author":"A Notarnicola","year":"2015","unstructured":"Notarnicola A, Lapadula G, Natuzzi D, Lundberg IE, Iannone F (2015) Correlation between serum levels of IL-15 and IL-17 in patients with idiopathic inflammatory myopathies. Scand J Rheumatol 44:224\u2013228","journal-title":"Scand J Rheumatol"},{"key":"5013_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1007\/s11926-012-0242-x","volume":"14","author":"A Tournadre","year":"2012","unstructured":"Tournadre A, Miossec P (2012) Interleukin-17 in inflammatory myopathies. Curr Rheumatol Rep 14:252\u2013256","journal-title":"Curr Rheumatol Rep"},{"key":"5013_CR18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009742.2010.517215","volume":"40","author":"H Shen","year":"2011","unstructured":"Shen H, Xia L, Lu J, Xiao W (2011) Interleukin-17 and interleukin-23 in patients with polymyositis and dermatomyositis. Scand J Rheumatol 40:217\u2013220","journal-title":"Scand J Rheumatol"},{"key":"5013_CR19","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.nmd.2014.06.432","volume":"24","author":"EM Moran","year":"2014","unstructured":"Moran EM, Mastaglia FL (2014) The role of interleukin-17 in immune-mediated inflammatory myopathies and possible therapeutic implications. Neuromuscul Disord 24:943\u2013952","journal-title":"Neuromuscul Disord"},{"key":"5013_CR20","first-page":"125","volume":"137","author":"G Chevrel","year":"2003","unstructured":"Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P (2003) Interleukin-17 increases the effects of IL-1 h on muscle cells : arguments for the role of T cells in the pathogenesis of myositis. J Neuro-Oncol 137:125\u2013133","journal-title":"J Neuro-Oncol"},{"key":"5013_CR21","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1136\/annrheumdis-2017-211401","volume":"76","author":"LG Rider","year":"2017","unstructured":"Rider LG, Aggarwal R, Pistorio A, Bayat N, Erman B, Feldman BM, Huber AM, Cimaz R, Cuttica RJ, de Oliveira SK, Lindsley CB, Pilkington CA, Punaro M, Ravelli A, Reed AM, Rouster-Stevens K, van Royen-Kerkhof A, Dressler F, Saad Magalhaes C, Constantin T, Davidson JE, Magnusson B, Russo R, Villa L, Rinaldi M, Rockette H, Lachenbruch PA, Miller FW, Vencovsky J, Ruperto N, International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation (2017) 2016 American College of Rheumatology\/European League against rheumatism criteria for minimal, moderate, and major clinical response in juvenile dermatomyositis. Ann Rheum Dis 76:782\u2013791","journal-title":"Ann Rheum Dis"},{"key":"5013_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1002\/acr.20035","volume":"62","author":"LLG Rider","year":"2010","unstructured":"Rider LLG, Koziol D, Giannini EEH, Jain MS, Smith MR, Whitney-Mahoney K, Feldman BM, Wright SJ, Lindsley CB, Pachman LM, Villalba ML, Lovell DJ, Bowyer SL, Plotz PH, Miller FW, Hicks JE (2010) Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res 62:465\u2013472","journal-title":"Arthritis Care Res"},{"key":"5013_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1477-7525-1-20","volume":"1","author":"B Bruce","year":"2003","unstructured":"Bruce B, Fries JF (2003) The Stanford health assessment questionnaire: dimensions and practical applications. Health Qual Life Outcomes 1:1\u20136","journal-title":"Health Qual Life Outcomes"},{"key":"5013_CR24","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V et al (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40:1462\u20131473","journal-title":"Rheumatology"},{"key":"5013_CR25","doi-asserted-by":"publisher","first-page":"909","DOI":"10.6061\/clinics\/2013(07)04","volume":"68","author":"MG Cruellas","year":"2013","unstructured":"Cruellas MG, Dos Santos VV, Levy-Neto M, Souza FHC, Shinjo SK (2013) Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics 68:909\u2013914","journal-title":"Clinics"},{"key":"5013_CR26","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s42358-019-0048-x","volume":"59","author":"FHC Souza","year":"2019","unstructured":"Souza FHC, Ara\u00fajo DB, Vilela VS, Bezerra MC, Sim\u00f5es RS, Bernardo WM et al (2019) Guidelines of the Brazilian Society of Rheumatology for the treatment of systemic autoimmune myopathies. Adv Rheumatol 59:6","journal-title":"Adv Rheumatol"},{"key":"5013_CR27","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/j.1445-5994.2010.02164.x","volume":"41","author":"M Dugar","year":"2011","unstructured":"Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ (2011) Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 41:674\u2013679","journal-title":"Intern Med J"},{"key":"5013_CR28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.3899\/jrheum.161480","volume":"44","author":"J Shi","year":"2017","unstructured":"Shi J, Li S, Yang H, Zhang Y, Peng Q, Lu X et al (2017) Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies. J Rheumatol 44:1051\u20131057","journal-title":"J Rheumatol"},{"key":"5013_CR29","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","volume":"56","author":"I Pinal-Fernandez","year":"2017","unstructured":"Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C et al (2017) A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Rheumatology (Oxford) 56:999\u20131007","journal-title":"Rheumatology (Oxford)"},{"key":"5013_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1590\/S0482-50042013000400007","volume":"53","author":"FHC Souza","year":"2013","unstructured":"Souza FHC, Cruellas MGP, Levy-Neto M, Shinjo SK (2013) S\u00edndrome antissintetase: Anti-PL-7, anti-PL-12 and anti-EJ. Rev Bras Reumatol 53:352\u2013357","journal-title":"Rev Bras Reumatol"},{"key":"5013_CR31","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s11926-013-0349-8","volume":"15","author":"B Hervier","year":"2013","unstructured":"Hervier B, Benveniste O (2013) Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 15:349","journal-title":"Curr Rheumatol Rep"},{"key":"5013_CR32","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.autrev.2014.01.022","volume":"13","author":"M Mahler","year":"2014","unstructured":"Mahler M, Miller FW, Fritzler MJ (2014) Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev 13:367\u2013371","journal-title":"Autoimmun Rev"},{"key":"5013_CR33","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","volume":"48","author":"M Sem","year":"2009","unstructured":"Sem M, Molber \u00d8, Lund MB, Gran JT (2009) Rituximab treatment of the anti-synthetase syndrome - a retrospective case series. Rheumatology 48:968\u2013971","journal-title":"Rheumatology"},{"key":"5013_CR34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s42358-018-0030-z","volume":"58","author":"FHC Souza","year":"2018","unstructured":"Souza FHC, Miossi R, De Moraes JCB, Bonf\u00e1 E, Shinjo SK (2018) Favorable rituximab response in patients with refractory idiopathic inflammatory myopathies. Adv Rheumatol 58:31","journal-title":"Adv Rheumatol"},{"key":"5013_CR35","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar1954","volume":"8","author":"M Vigna-Perez","year":"2006","unstructured":"Vigna-Perez M, Hern\u00e1ndez-Castro B, Paredes-Saharopulos O, Portales-P\u00e9rez D, Baranda L, Abud-Mendoza C et al (2006) Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 8:R83","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-05013-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-05013-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,8]],"date-time":"2021-03-08T19:31:23Z","timestamp":1615231883000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-05013-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,9]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["5013"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-05013-7","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,9]]},"assertion":[{"value":"15 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}